Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2021 Jul 2

PMID 34199522

Citations 30

Authors

Konstantinos Venetis

Roberto Piciotti

Elham Sajjadi

Marco Invernizzi

Stefania Morganti

Carmen Criscitiello

Nicola Fusco

Affiliations

Soon will be listed here.

Abstract

Despite the remarkable advances in the diagnosis and treatment of breast cancer patients, the presence or development of metastasis remains an incurable condition. Bone is one of the most frequent sites of distant dissemination and negatively impacts on patient's survival and overall frailty. The interplay between tumor cells and the bone microenvironment induces bone destruction and tumor progression. To date, the clinical management of bone metastatic breast cancer encompasses anti-tumor systemic therapies along with bone-targeting agents, aimed at slowing bone resorption to reduce the risk of skeletal-related events. However, their effect on patients' survival remains controversial. Unraveling the biology that governs the interplay between breast neoplastic cells and bone tissue would provide means for the development of new therapeutic agents. This article outlines the state-of-the art in the characterization and targeting the bone metastasis in breast cancer, focusing on the major clinical and translational studies on this clinically relevant topic.

Citing Articles

A rare case of a solitary osseous metastasis from breast carcinoma presenting with fluid-fluid levels on MRI.

Cubitt C, Ariyaratne S, Evans S, Vaiyapuri S, Hughes S, Botchu R Int Cancer Conf J. 2024; 13(4):401-406.

PMID: 39398900 PMC: 11464755. DOI: 10.1007/s13691-024-00698-y.

Deep bone oncology Diagnostics: Computed tomography based Machine learning for detection of bone tumors from breast cancer metastasis.

Zhao X, Dong Y, Xu L, Shen Y, Qin G, Zhang Z J Bone Oncol. 2024; 48:100638.

PMID: 39391583 PMC: 11466622. DOI: 10.1016/j.jbo.2024.100638.

Mortality associated with osteoporosis and pathological fractures in the United States (1999-2020): a multiple-cause-of-death study.

Huo R, Wei C, Huang X, Yang Y, Huo X, Meng D J Orthop Surg Res. 2024; 19(1):568.

PMID: 39285484 PMC: 11406831. DOI: 10.1186/s13018-024-05068-1.

Caffeic acid derivative MPMCA suppresses osteoclastogenesis and facilitates osteoclast apoptosis: implications for the treatment of bone loss disorders.

Thuong L, Hsu C, Chen H, Kuo Y, Tang C Aging (Albany NY). 2024; 16(16):11926-11938.

PMID: 39189924 PMC: 11386915. DOI: 10.18632/aging.206067.

Silencing Exosomal circ102927 Inhibits Foot Melanoma Metastasis via Regulating Invasiveness, Epithelial-Mesenchymal Transition and Apoptosis.

Wan H, Zhong L, Xia T, Zhang D Cancer Manag Res. 2024; 16:825-839.

PMID: 39044746 PMC: 11263183. DOI: 10.2147/CMAR.S460315.

References

Invernizzi M, Michelotti A, Noale M, Lopez G, Runza L, Giroda M . Breast Cancer Systemic Treatments and Upper Limb Lymphedema: A Risk-Assessment Platform Encompassing Tumor-Specific Pathological Features Reveals the Potential Role of Trastuzumab. J Clin Med. 2019; 8(2). PMC: 6406664. DOI: 10.3390/jcm8020138. View

Shen D, Zhu L, Liu Y, Peng Y, Lan M, Fang K . Efficacy evaluation and mechanism study on inhibition of breast cancer cell growth by multimodal targeted nanobubbles carrying AMD070 and ICG. Nanotechnology. 2020; 31(24):245102. DOI: 10.1088/1361-6528/ab7e73. View

Lehmann J, Thiele S, Baschant U, Rachner T, Niehrs C, Hofbauer L . Mice lacking DKK1 in T cells exhibit high bone mass and are protected from estrogen-deficiency-induced bone loss. iScience. 2021; 24(3):102224. PMC: 7961106. DOI: 10.1016/j.isci.2021.102224. View

Kim B, Kim H, Jung S, Moon A, Noh D, Lee Z . A CTGF-RUNX2-RANKL Axis in Breast and Prostate Cancer Cells Promotes Tumor Progression in Bone. J Bone Miner Res. 2019; 35(1):155-166. DOI: 10.1002/jbmr.3869. View

Himelstein A, Foster J, Khatcheressian J, Roberts J, Seisler D, Novotny P . Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA. 2016; 317(1):48-58. PMC: 5321662. DOI: 10.1001/jama.2016.19425. View

Hao Y, Baker D, Ten Dijke P . TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis. Int J Mol Sci. 2019; 20(11). PMC: 6600375. DOI: 10.3390/ijms20112767. View

Rieunier G, Wu X, Macaulay V, Lee A, Weyer-Czernilofsky U, Bogenrieder T . Bad to the Bone: The Role of the Insulin-Like Growth Factor Axis in Osseous Metastasis. Clin Cancer Res. 2019; 25(12):3479-3485. DOI: 10.1158/1078-0432.CCR-18-2697. View

Drake M, Clarke B, Khosla S . Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008; 83(9):1032-45. PMC: 2667901. DOI: 10.4065/83.9.1032. View

Jaschke N, Sipos W, Hofbauer L, Rachner T, Rauner M . Skeletal endocrinology: where evolutionary advantage meets disease. Bone Res. 2021; 9(1):28. PMC: 8163738. DOI: 10.1038/s41413-021-00149-x. View

10.

Brook N, Brook E, Dharmarajan A, Dass C, Chan A . Breast cancer bone metastases: pathogenesis and therapeutic targets. Int J Biochem Cell Biol. 2018; 96:63-78. DOI: 10.1016/j.biocel.2018.01.003. View

11.

Morimoto A, Kikuta J, Nishikawa K, Sudo T, Uenaka M, Furuya M . SLPI is a critical mediator that controls PTH-induced bone formation. Nat Commun. 2021; 12(1):2136. PMC: 8035405. DOI: 10.1038/s41467-021-22402-x. View

12.

Aleckovic M, McAllister S, Polyak K . Metastasis as a systemic disease: molecular insights and clinical implications. Biochim Biophys Acta Rev Cancer. 2019; 1872(1):89-102. PMC: 6692219. DOI: 10.1016/j.bbcan.2019.06.002. View

13.

Wang L, Fang D, Xu J, Luo R . Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review. BMC Cancer. 2020; 20(1):1059. PMC: 7607850. DOI: 10.1186/s12885-020-07568-9. View

14.

Monteran L, Ershaid N, Sabah I, Fahoum I, Zait Y, Shani O . Bone metastasis is associated with acquisition of mesenchymal phenotype and immune suppression in a model of spontaneous breast cancer metastasis. Sci Rep. 2020; 10(1):13838. PMC: 7429866. DOI: 10.1038/s41598-020-70788-3. View

15.

Dunn L, Mohammad K, Fournier P, McKenna C, Davis H, Niewolna M . Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS One. 2009; 4(9):e6896. PMC: 2731927. DOI: 10.1371/journal.pone.0006896. View

16.

Boyce B, Li J, Xing L, Yao Z . Bone Remodeling and the Role of TRAF3 in Osteoclastic Bone Resorption. Front Immunol. 2018; 9:2263. PMC: 6172306. DOI: 10.3389/fimmu.2018.02263. View

17.

Shupp A, Kolb A, Mukhopadhyay D, Bussard K . Cancer Metastases to Bone: Concepts, Mechanisms, and Interactions with Bone Osteoblasts. Cancers (Basel). 2018; 10(6). PMC: 6025347. DOI: 10.3390/cancers10060182. View

18.

Jeong H, Jeong J, Kim J, Ahn J, Jung K, Koh S . Final results of the randomized phase 2 LEO trial and bone protective effects of everolimus for premenopausal hormone receptor-positive, HER2-negative metastatic breast cancer. Int J Cancer. 2021; . DOI: 10.1002/ijc.33613. View

19.

Pagni F, Guerini-Rocco E, Schultheis A, Grazia G, Rijavec E, Ghidini M . Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers. Int J Mol Sci. 2019; 20(21). PMC: 6862285. DOI: 10.3390/ijms20215452. View

20.

Kijima Y, Kondo N, Okumura G, Endo N . Bone Histomorphometry of Femoral Head Cancellous Bone in Patients Who Underwent Total Hip Arthroplasties due to Destructive Hip in Rheumatoid Arthritis. Acta Med Okayama. 2021; 75(2):125-131. DOI: 10.18926/AMO/61878. View